ERBB2 and neoplasm: Existing biomarkers associated with drug resistance mostly focus on tumor cells themselves (e.g., ER/PR expression, HER2 amplification, BRCA mutations), while overlooking the regulatory role of the tumor microenvironment (TME) [12,13].